|
|
|
| Effect of Concurrent Radiotherapy and Chemotherapy on Survival Rate and Serum TSP-1 and MicroRNA-21 Levels in Patients with Esophageal Cancer |
| JI Xiang, ZHOU Linlin, PAN Jiqun, et al |
| Dongtai People's Hospital, Jiangsu Dongtai 224200, China |
|
|
|
|
Abstract Objective: To study the effect of concurrent radiotherapy and chemotherapy on survival rate and serum TSP-1 and microRNA-21 levels in patients with esophageal cancer. Methods: 110 esophageal cancer patients who received therapy from February 2015 to January 2017 in our hospital were selected as research objects. According to simple random grouping method,those patients were divided into the observation group (n=59) and the control group (n=51). The control group was treated with sequential chemoradiotherapy, while the observation group was treated with concurrent radiotherapy and chemotherapy. Post-treatment comparison between both groups was made in the total remission rate, 1-year and 2-year survival rate, serum TSP-1, microRNA-21 level, Karnofsky(KPS) score, and adverse reactions. Results:After treatment, the total remission rate of the observation group was significantly higher than that of the control group[88.14％(52/59)vs66.67％(34/51)](P＜0.05). There was no significant difference in 1-year survival rate between the two groups (P>0.05). The 2-year survival rate of the observation group was significantly higher than that of the control group[71.19％(42/59)vs33.3％(17/51)](P<0.05). Serum Thrombin sensitive protein-1(TSP-1) and microRNA-21 levels were significantly higher than those in the control group[(189.63±9.20)ng/mL vs(145.86±7.49)ng/mL,(6.96±1.05)-log vs(12.82±2.04)-log](P<0.05). KPS score was significantly higher than that of the control group[(75.38±3.59)ng/mL vs(64.92±3.05)ng/mL](P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Synchronous radiotherapy and chemotherapy can effectively improve the clinical symptoms, improve the survival rate of patients, inhibit tumor recurrence and metastasis, and promote the prognosis of patients.
|
|
|
|
|
|
[1] 曹小琴,孙喜斌.食管癌发病水平及变化趋势[J].中国肿瘤临床,2016,43(21):932~936.
[2] Hall K A, Spicer M T, Ilich J Z, et al. Nutritional care for patients with esophageal cancer[J]. Topics in Clinical Nutrition, 2019, 34(1):2~13.
[3] Su W W, Chuang S, Yen A M, et al. Risk for a second primary hypopharyngeal and esophageal cancer after an initial primary oral cancer[J]. Oral Diseases, 2019, 25(4):1067~1075.
[4] Ogasawara A, Kamiya M, Sakamoto K, et al. Red fluorescence probe targeted to dipeptidylpeptidase-IV for highly sensitive detection of esophageal cancer[J]. Bioconjugate Chemistry, 2019, 30(4):1055~1060.
[5] Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2012[J]. Esophagus, 2019, 16(3):1~25.
[6] Abiad J M E, Hales R K, Levin A S, et al. Soft-tissue metastases from esophageal cancer[J]. Journal of Gastrointestinal Surgery, 2019, 23(9):1721~1728.
[7] 许亚萍,毛伟敏.食管癌新辅助放化疗后疗效显著患者序贯治疗的选择[J].中国肿瘤,2015,24(11):938~943.
[8] 庄璐,马丹,李兆申.食管癌危险因素研究进展[J].胃肠病学和肝病学杂志,2015,24(9):1141~1145.
[9] 谢丽敏,杨文清.新辅助放化疗治疗食管癌血清TSP-1、VEGF变化[J].心理月刊,2019,14(9):135.
[10] 江文洋,任杰,范国华,等.microRNA和食管癌关系的研究进展[J].现代肿瘤医学,2015,23(13):1931~1934. |
|
|
|
2020, Vol. 26 
